RSS-Feed abonnieren
DOI: 10.1055/s-0042-1746997
Treatment option of systemic hypereosinophilia under dupilumab therapy
Hypereosinophilia with systemic manifestations may rapidly occur under dupilumab therapy for nasal polyps without previous signs of systemic involvement or anti-IL5/R treatment. In providing two examples we present potential strategies for the treatment of hypereosinophilia occurring under treatment with dupilumab.
The first patient was being treated for asthma and nasal polyps without systemic hypereosinophilia. Under dupilumab therapy he rapidly developed systemic hypereosinophilia. A switch to benralizumab led to effective treatment of hypereosinophilia and was well tolerated by the patient.
The second patient suffered from asthma, nasal polyps and eosinophilic granulomatosis with poliangitis. Sufficient control of asthma, nasal polyps and hypereosinophilia could not be achieved neither under monotherapy with dupilumab nor mepolizumab nor benralizumab. After initiating dual therapy with dupilumab and benralizumab sufficient control of asthma, nasal polyps and systemic hypereosinophilia was achieved. After 1,5 years of dual therapy no severe complications or side-effects such as antibody-antibody interactions have been observed.
Dual therapy with anti-IL5/R and dupilumab might be an option when anti-IL5/R treatment alone is insufficient, or when symptomatic hypereosinophilia occurs under dupilumab treatment.
Publikationsverlauf
Artikel online veröffentlicht:
24. Mai 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,Germany